

**Date:** 13 February 2026

To  
**BSE Limited**  
2<sup>nd</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street, Fort,  
Mumbai - 400001, MH

**Subject: Outcome of the Board Meeting of the Company**  
**Reference: BSE Symbol: SAMPRE: BSE Scrip Code: 530617**

Sir / Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosures) Requirements, 2015 (“**Listing Regulations**”), and in reference to our intimation dated 10 February 2026, we wish to inform you that the Board of Directors of Sampre Nutritions Limited (“**the Company**”) at their meeting held today i.e., 13 February 2026, have inter-alia:

1. Appointed Pradeep Narendra Poddar (DIN: 00025199) as a non-executive non-independent additional director.

We hereby inform you that the Board of Directors of the Company at its meeting held on 13 February 2026, on the recommendation of the Nomination and Remuneration Committee, has considered and approved the appointment of Pradeep Narendra Poddar (DIN: 00025199) as a non-executive non-independent additional director with effect from 13 February 2026. The aforesaid appointment is subject to approval of shareholders of the Company in terms of Regulation 17(1C) of the Listing Regulations. The details as required in accordance with Regulation 30(3) read with Para A(7) of Part A of Schedule III of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, are enclosed as **Annexure B**. Further, in terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015 it is declared that Vinay Kumar Verma do not hold any shares in the Company and as per BSE Circular No. LIST/COMP/14/2018-19 dated 20 June 2018 he is not debarred from holding the office of the Director by virtue of any order of the Securities and Exchange Board of India or any other regulatory authority.

2. Approved the standalone and consolidated unaudited financial results of the Company for the third quarter and nine-month period ended 31 December 2025.

Under Regulation 33 of the Listing Regulations, the copy of the standalone and consolidated unaudited financial results of the Company for the third quarter and nine-month period ended 31 December 2025, accompanied by the limited review reports issued by the statutory auditors of the Company, are enclosed as **Annexure A**.

The Board Meeting commenced at 1:30 P.M. (IST) and concluded on 4:30 P.M. (IST).

**Sampre Nutritions Limited**  
*Outcome of Board Meeting*

Kindly take the above information on record and acknowledge the receipt of the same. Thanking You.

Sincerely,

**For Sampre Nutritions Limited**

**Brahma Gurbani**  
**Managing Director**  
**(DIN: 00318180)**

**Enclosed:** As attached

**Annexure A**

**DISCLOSURE AS REQUIRED UNDER REGULATION 30(3) READ WITH PARA A(7) OF PART A OF SCHEDULE III OF THE LISTING REGULATIONS AND THE SEBI MASTER CIRCULAR NO. SEBI MASTER CIRCULAR NO. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 DATED 30 JANUARY 2026 WITH REGARDS TO APPOINTMENT OF A DIRECTOR ARE AS UNDER:**

---

<b>Sl. No.</b>	<b>Particulars</b>	<b>Description</b>
1.	Reason for change viz. appointment, <del>reappointment, resignation, removal, death or otherwise</del>	Appointment of Pradeep Narendra Poddar (DIN: 00025199) as a non-executive non-independent additional director of the Company
2.	Date of appointment / <del>reappointment / cessation</del> and term of appointment / <del>reappointment</del>	13 February 2026
3.	Brief profile (in case of appointment)	He holds a Masters Degree in Business Management and a Bachelors Degree in Chemical Engineering. He has around four decades of experience in food processing industry.
4.	Disclosure of relationships between directors ( <i>in case of appointment of a director</i> )	Pradeep Narendra Poddar is not related to any directors of the Company

**Annexure B**  
*(on the next page)*

<This space has been left blank intentionally>

## SAMPRE NUTRITIONS LIMITED

CIN: L15499TG1991PLC013515

Registered Office: Plot No.133, Industrial Estate, Medchal – 501 401.

Website: www.sampreltd.com; Email: gurbani@gurbanigroup.in

Statement of Standalone Un-Audited Financial Results for the Quarter & Nine Months ended 31st December, 2025

( In Lakhs)

Particulars	Quarter ended			Year to date period ended		Financial Year ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I Revenue from operations	738.51	999.74	557.80	2,824.90	1,735.89	2512.42
II Other income	0.05	0.54	4.38	3.09	6.91	37.45
III <b>Total Revenue (I + II)</b>	<b>738.56</b>	<b>1,000.28</b>	<b>562.18</b>	<b>2827.99</b>	<b>1742.80</b>	<b>2,549.87</b>
IV <b>Expenses:</b>						
Cost of materials consumed	149.32	323.73	130.42	869.59	349.67	836
Purchases of Stock-in-Trade	-	-	-	-	-	-
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
Employee benefits expense	137.84	269.47	253.22	724.18	675.75	1080.59
Finance costs	26.30	28.34	58.57	85.45	148.60	183.28
Depreciation and amortization expense	50.12	60.97	43.52	150.35	130.56	197.03
Other expenses	298.68	211.62	130.17	794.10	454.85	969.15
<b>Total expenses</b>	<b>662.26</b>	<b>894.13</b>	<b>615.90</b>	<b>2623.67</b>	<b>1759.43</b>	<b>3266.05</b>
V <b>Profit before exceptional and extraordinary items and tax (III - IV)</b>	<b>76.30</b>	<b>106.15</b>	<b>(53.72)</b>	<b>204.32</b>	<b>(16.63)</b>	<b>(716.18)</b>
VI Exceptional items	-	-	-	-	-	-
VII <b>Profit before tax (V - VI)</b>	<b>76.30</b>	<b>106.15</b>	<b>(53.72)</b>	<b>204.32</b>	<b>(16.63)</b>	<b>(716.18)</b>
VIII <b>Tax expense:</b>						
(1) Current tax	10.46	16.68	-	27.14	-	-
(2) Deferred tax	-	-	-	-	-	14.74
IX <b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>65.84</b>	<b>89.47</b>	<b>(53.72)</b>	<b>177.18</b>	<b>(16.63)</b>	<b>(730.92)</b>
X Profit/(loss) from discontinuing operations	-	-	-	-	-	-
XI Tax expense of discontinuing operations	-	-	-	-	-	-
XII <b>Profit/(loss) from Discontinuing operations (after tax) (X-XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII <b>Profit (Loss) for the period (IX + XII)</b>	<b>65.84</b>	<b>89.47</b>	<b>(53.72)</b>	<b>177.18</b>	<b>(16.63)</b>	<b>(730.92)</b>
XIV <b>Other Comprehensive Income</b>						
- Items that will not be reclassified to profit or loss	-	-	-	-	-	-
- Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
- Items that will be reclassified to profit or loss	-	-	-	-	-	-
- Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV <b>Total comprehensive income for the period (XIII+XIV)</b>	<b>65.84</b>	<b>89.47</b>	<b>(53.72)</b>	<b>177.18</b>	<b>(16.63)</b>	<b>(730.92)</b>
XVI <b>Earnings per equity share:</b>						
(1) Basic	0.07	0.14	(0.30)	0.19	(0.09)	(3.48)
(2) Diluted	0.07	0.14	(0.29)	0.19	(0.09)	(5.17)

### NOTES:

- The results have been prepared in accordance with the India Accounting Standards ("Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 as amended.
- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors in their respective meetings held on 13.02.2026 These results have been subject to limited review by the Statutory Auditors.
- Figures of previous year have been regrouped wherever necessary to make them comparable.

For SAMPRE NUTRITIONS LIMITED

Date: 13.02.2026

Place : Medchal

**BRAHMA GURBANI**  
Managing Director

(CIN: L15499TG1991PLC013515)

Regd. Off & Work: Unit-1: Plot No. 133, I.E, Medchal-501401. Telangana, India. Ph: +91-8418-222428

Unit-2: Plot No. 127,128, Royes Building, I.E.Medchal, Malkajgiri-501401.Telangana.

E-mail:gurbani@gurbanigroup.in, www.gurbanigroup.in.

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

Review Report

To The Board of Directors

**Sampre Nutritions Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Sampre Nutritions Limited** ("the Company") for the quarter ended 31<sup>st</sup> December 2025 and the Year to date from 1<sup>st</sup> April 2025 to 31<sup>st</sup> December 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable Indian Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For N G Rao & Associates**  
**Chartered Accountants**  
**Firm Registration No. 009399S**

**Nageswara Rao G**  
**Partner**  
**Membership No. 207300**  
**UDIN: 26207300CQCBKK7214**

**Date: 13<sup>th</sup> February 2026**  
**Place: Hyderabad**

## SAMPRE NUTRITIONS LIMITED

CIN: L15499TG1991PLC013515

Registered Office: Plot No.133, Industrial Estate, Medchal – 501 401.

Website: www.sampre ltd.com; Email: gurbani@gurbanigroup.in

Statement of Consolidated Un-Audited Financial Results for the Quarter & Nine Months ended 31st December, 2025

( In Lakhs)

Particulars	Quarter ended			Year to date period ended		Financial Year ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
I Revenue from operations	738.51	999.74	557.80	2,824.90	1,735.89	2512.42
II Other income	0.05	0.54	4.38	3.09	6.91	37.45
III <b>Total Revenue (I + II)</b>	<b>738.56</b>	<b>1,000.28</b>	<b>562.18</b>	<b>2827.99</b>	<b>1742.80</b>	<b>2,549.87</b>
IV <b>Expenses:</b>						
Cost of materials consumed	149.32	323.73	130.42	869.59	349.67	836.00
Purchases of Stock-in-Trade	-	-	-	-	-	-
Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-	-	-	-	-	-
Employee benefits expense	137.84	269.47	253.22	724.18	675.75	1080.59
Finance costs	26.30	28.34	58.57	85.45	148.60	206.57
Depreciation and amortization expense	50.12	60.97	43.52	150.35	130.56	197.03
Other expenses	302.78	211.44	130.64	798.20	470.07	982.17
<b>Total expenses</b>	<b>666.36</b>	<b>893.95</b>	<b>616.37</b>	<b>2627.77</b>	<b>1774.65</b>	<b>3302.36</b>
V <b>Profit before exceptional and extraordinary items and tax (III - IV)</b>	<b>72.20</b>	<b>106.33</b>	<b>(54.19)</b>	<b>200.22</b>	<b>(31.85)</b>	<b>(752.49)</b>
VI Exceptional items	-	-	-	-	-	-
VII <b>Profit before tax (V - VI)</b>	<b>72.20</b>	<b>106.33</b>	<b>(54.19)</b>	<b>200.22</b>	<b>(31.85)</b>	<b>(752.49)</b>
VIII <b>Tax expense:</b>						
(1) Current tax	10.46	16.68	-	27.14	-	-
(2) Deferred tax	-	-	-	-	-	14.74
IX <b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>61.74</b>	<b>89.65</b>	<b>(54.19)</b>	<b>173.08</b>	<b>(31.85)</b>	<b>(767.23)</b>
X Profit/(loss) from discontinuing operations	-	-	-	-	-	-
XI Tax expense of discontinuing operations	-	-	-	-	-	-
XII <b>Profit/(loss) from Discontinuing operations (after tax) (X-XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII <b>Profit (Loss) for the period (IX + XII)</b>	<b>61.74</b>	<b>89.65</b>	<b>(54.19)</b>	<b>173.08</b>	<b>(31.85)</b>	<b>(767.23)</b>
XIV <b>Other Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
- Items that will not be reclassified to profit or loss	-	-	-	-	-	-
- Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
- Items that will be reclassified to profit or loss	-	-	-	-	-	-
- Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV <b>Total comprehensive income for the period (XIII+XIV)</b>	<b>61.74</b>	<b>89.65</b>	<b>(54.19)</b>	<b>173.08</b>	<b>(31.85)</b>	<b>(767.23)</b>
XVI <b>Earnings per equity share:</b>						
(1) Basic	0.06	0.14	(0.30)	0.18	(0.18)	(3.65)
(2) Diluted	0.06	0.14	(0.29)	0.18	(0.17)	(5.43)

### NOTES:

- The results have been prepared in accordance with the India Accounting Standards ("Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 as amended.
- The above results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors in their respective meetings held on 13.02.2026. These results have been subject to limited review by the Statutory Auditors.
- Figures of previous year have been regrouped wherever necessary to make them comparable.

For SAMPRE NUTRITIONS LIMITED

Date: 13.02.2026

Place : Medchal

**BRAHMA GURBANI**  
Managing Director

(CIN: L15499TG1991PLC013515)

Regd. Off & Work: Unit-1: Plot No. 133, I.E, Medchal-501401. Telangana, India. Ph: +91-8418-222428

Unit-2: Plot No. 127,128, Royes Building, I.E.Medchal, Malkajiri-501401.Telangana.

E-mail:gurbani@gurbanigroup.in, www.gurbanigroup.in.

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review report to**  
**The Board of Directors**  
**Sampre Nutritions Limited**

We have reviewed the accompanying statement of unaudited consolidated financial results of **Sampre Nutritions Limited** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended 31<sup>st</sup> December, 2025 and for the period from 01<sup>st</sup> April 2025 to 31<sup>st</sup> December 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

S. No.	Name of the Entity	Relationship with the Holding Company
1	SAMPRE NUTRITIONS HOLDING LIMITED	100% Subsidiary
2	SAMPRE NUTRITIONS-FZCO	100% Subsidiary

Based on our review conducted and procedures performed as stated above; nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial statements / financial information / financial results of two subsidiaries included in the consolidated unaudited financial results, whose interim financial results include total revenue Rs. 0.00 Lakhs and net loss of Rs. (4.10) lakhs for the quarter ended 31<sup>st</sup> December 2025, respectively, as considered in the consolidated unaudited financial results. These interim financial statements / financial information / financial results have not been reviewed by their auditors. These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiary is based solely on such unaudited interim financial results and other unaudited financial information.

Our conclusion on the Statement in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management.

**For N G Rao & Associates.**  
**Chartered Accountants**  
**Firm Reg No: 009399S**

**G Nageswara Rao**  
**Partner**  
**Membership No:207300**  
**UDIN: 26207300BPOFEQ7045**

**Place: Hyderabad**  
**Date: 13-02-2026**